Form 4: ProMIS Neurosciences Executive Granted Stock Options

Johanne Kaplan, Chief Development Officer at ProMIS Neurosciences, was granted stock options for 175,000 common shares.

Summary

• Johanne Kaplan, the Chief Development Officer of ProMIS Neurosciences, was granted options to purchase 175,000 common shares.
• The options have an exercise price of $1 per share.
• The options were granted on November 18, 2024.
• 25% of the options will vest on November 18, 2025, and the remaining options will vest ratably over the following 36 months.
• The options expire on November 18, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative issues.

Positives

• The granting of stock options aligns the interests of the Chief Development Officer with the long-term success of the company.
• The vesting schedule encourages continued service and contribution from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, similar to companies like Biogen and Amgen.
• The vesting schedule of 25% after one year and the remainder over 36 months is a typical vesting structure for executive stock options.

Stakeholder Impact

• The stock option grant may have a minor dilutive effect on existing shareholders if the options are exercised.

Key Dates

Keywords

stock options, executive compensation, insider trading, ProMIS Neurosciences, PMN, vesting, equity